Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on August 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Berens has given his Buy rating due to a combination of factors, primarily driven by AstraZeneca’s strong performance in the oncology segment. The company reported total product sales that exceeded expectations, with significant contributions from key oncology products such as Enhertu, Imfinzi, Lynparza, Tagrisso, and Calquence. This robust performance in oncology, along with promising growth prospects in cardiovascular, respiratory, and immunology segments, supports the company’s ambitious revenue targets for 2030.
Additionally, AstraZeneca’s management has demonstrated confidence in mitigating potential impacts from new tariffs on EU imports by leveraging their manufacturing capabilities in the US. The company’s strategic initiatives and pipeline developments, particularly in oncology, further bolster the growth outlook. These factors, combined with the company’s ability to meet and potentially exceed its revenue targets, underpin Andrew Berens’s Buy rating for AstraZeneca.
In another report released on August 1, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $84.00 price target.